Kevin C. Tang

Kevin C. Tang, listed as chief executive, has filed trades across 6 companies (mainly through SEC (Form 4)), most often in La Jolla Pharmaceutical Co, TCR2 Therapeutics Inc. and Rain Therapeutics Inc. The record holds 19 filings, for trades running from 24 May 2021 to 26 January 2024.

On the open market, the record shows 9 purchases worth €1.1M and 5 sales worth €4.1M. Netting one side against the other leaves €3.1M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price.

In size, the median ticket on the buying side is €69k. On 2 out of 9 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 14 February 2024 with a transaction in TCR2 Therapeutics Inc. The last insider purchase was made public on 13 October 2023, 1,101 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.